A Multicenter, Retrospective Study (RE-ENACT 2) on RazumabTM (World's First Biosimilar Ranibizumab) in Retinal Vein Occlusion

The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

© The authors, CC-BY-NC 2020